Syed Hamzah Ali

T32 CV Outcomes Research @MidAmericaHeart | @DellMedImRes 25’| @MCG_AUG 22’ | @UniversityofGa 18’ | Aspiring Cardiologist | Views = My Own

[OpenSource Cardiology @opensourcecards]

Did CARDIO-TTRansform fail, or did it answer a different question? The effect of eplontersen depended on background stabilizer therapy.

New article at @opensourcecardiology walks through the monotherapy signal, the pooled silencer data, and why percent knockdown is harder to compare than it looks.

@BrettSperryMD @HamzahAliMD
https://t.co/twBI1p2MLT

[Brett Sperry, MD @BrettSperryMD]

🔥 Our thoughts on all things CARDIO-TTRansform

A lot of nuance to unpack here, and hopefully more analyses of this study will shed light on the monotherapy vs combination therapy subgroups.

Attached is our reproduction of the all cause mortality curves for the monotherapy populations across all 4 ATTR-CM trials (Panel A) and the overall study populations (Panel B).

Good news for patients is that we keep creeping closer and closer to the age expected survival in the modern era!

[OpenSource Cardiology @opensourcecards]

🆕CARDIO-TTRansform, the largest treatment trial yet in ATTR-CM (1,432 patients), missed its primary endpoint: rate ratio 0.89 (95% CI 0.73 to 1.09).

But baseline stabilizer use modified the effect of eplontersen (P for interaction = .017):
• Not on a stabilizer at baseline: RR 0.71 (95% CI 0.54 to 0.93), a nominally 29% lower rate of CV death and recurrent CV events
• Already on a stabilizer: RR 1.14 (95% CI 0.85 to 1.53)

In a Critical Appraisal, @HamzahAliMD, Andrew A. Girard, and @BrettSperryMD argue this reflects the limited incremental benefit of adding a silencer to a stabilizer, not an ineffective drug.

They also unpack why percent TTR knockdown is hard to compare across silencers and reflect on where combination stabilizer and silencer therapy goes from here.

https://t.co/twBI1p3kBr

[Syed Hamzah Ali @HamzahAliMD]

@utmbcardiology @MShalabCardUTMB @khaledchatila1 @utmbhealth Congratulations @utmbcardiology!! I would love for the opportunity to interview here for fellowship and be part of the team!

[Syed Hamzah Ali @HamzahAliMD]

Excited to share our publication in JACC Case Reports on the role of cardiac MRI in diagnosing chronic chagas cardiomyopathy!! @JACCJournals @ACCinTouch

https://t.co/hQ7wbCBMcP

[Syed Hamzah Ali @HamzahAliMD]

5. Ali, S, Abdullah, Y, Rodgers, G. PREDICTING HEART DISEASE MORTALITY IN TEXAS: MACHINE LEARNING INSIGHTS ON SOCIOECONOMIC AND HEALTHCARE ACCESS DISPARITIES. JACC. 2025 Apr, 85 (12_Supplement) 375. https://t.co/FVmU2009ec

[Syed Hamzah Ali @HamzahAliMD]

I had a wonderful time presenting my abstracts at National ACC in Chicago this past weekend. Thank you to my mentors and colleagues for your support!

@ACCinTouch @txchapteracc @DellMedCardio

[Syed Hamzah Ali @HamzahAliMD]

4. Ali, S, Abouelnaaj, M, Piroozi, A. et al. COST-EFFECTIVENESS OF OZEMPIC VERSUS BARIATRIC SURGERY FOR LONG-TERM WEIGHT MANAGEMENT: A 10-YEAR MARKOV MODEL. JACC. 2025 Apr, 85 (12_Supplement) 408. https://t.co/2X7YtYXOS4

[Syed Hamzah Ali @HamzahAliMD]

3. Ali, S, Gupta, M, Abdullah, Y. et al. ENHANCING READABILITY IN PATIENT EDUCATION: A COMPARATIVE ANALYSIS OF AI-GENERATED AND COMMERCIAL HEART FAILURE DISCHARGE INSTRUCTIONS. JACC. 2025 Apr, 85 (12_Supplement) 1569. https://t.co/fsjUY0h9yc

[Syed Hamzah Ali @HamzahAliMD]

2. Ali, S, Khan, U, Pham, H. et al. CULTURE-NEGATIVE ENDOCARDITIS IN A PATIENT WITH RHEUMATOID ARTHRITIS AND A BIOPROSTHETIC VALVE. JACC. 2025 Apr, 85 (12_Supplement) 4058. https://t.co/GKPJqecbRT

[Syed Hamzah Ali @HamzahAliMD]

1. Ali, S, Seghers, M, Pham, H. et al. FULMINANT MYOCARDITIS IN THE SETTING OF ACUTE HIV AND GROUP A STREPTOCOCCUS PHARYNGITIS. JACC. 2025 Apr, 85 (12_Supplement) 4333.
https://t.co/SQ8JJzYjTl

[Syed Hamzah Ali @HamzahAliMD]

@txchapteracc When will the abstract submission link open?

[Syed Hamzah Ali @HamzahAliMD]

I had a wonderful time learning from experts in cardiology, sharing research, and meeting new friends and mentors at #ACC2024 in Atlanta this weekend! @ACCinTouch @DellMedCardio

[Syed Hamzah Ali @HamzahAliMD]

I am excited to officially announce that I will be staying at UT Austin Dell Med IM Residency an additional year to serve as inpatient chief!

[Syed Hamzah Ali @HamzahAliMD]

@auugamp Congratulations, well deserved Dean Nuss!!

[AU/UGA Medical Partnership @auugamp]

Dr. Shelley Nuss has been named the founding dean of the UGA School of Medicine.

https://t.co/mIRkGql0mj

[Dell Medical School @DellMedSchool]

To all our residents and fellows: thank you! You provide our community with 575,000 hours of care each year, work on some of the most medically complex cases, and make us better educators and clinicians.

[JACC Journals @JACCJournals]

#Clopidogrel monotherapy following 1-month #DAPT is associated with numerically lower rate of composite CV outcomes and significantly ⬇️ CV events compared with #aspirin monotherapy following 12-month DAPT. https://t.co/cdbxy1PT4Z

#JACC #PCI #STOPDAPT2 @HirotWatanabeMD

[American College of Cardiology @ACCinTouch]

Congratulations to all who had abstracts accepted for #ACC24! 🎉

Don't miss out on the opportunity to watch your colleagues present their science! Register today: https://t.co/yT1LRiJT0b

[Syed Hamzah Ali @HamzahAliMD]

Excited to have 2 abstracts accepted to present at ACC in Atlanta, GA! #ACC24

“SILENT INVADER: CHRONIC CHAGAS CARDIOMYOPATHY UNMASKED BY VF CARDIAC ARREST AND SUSTAINED VT - A CASE SERIES"

“A RARE PHENOMENON: ACUTE SYSTOLIC HEART FAILURE 2/2 MACROPHAGE ACTIVATION SYNDROME"